Home > Oncology > ASCO 2021 > Paediatric Cancer > Circulating tumour DNA to evaluate response in children with neuroblastoma

Circulating tumour DNA to evaluate response in children with neuroblastoma

Presented By
Dr Kevin Campbell, Dana-Farber Cancer Institute, MA, USA
Conference
ASCO 2021
Trial
Phase 2, NANT2011-01
In the phase 2 NANT2011-01 trial, levels of circulating tumour DNA (ctDNA) were evaluated during treatment. In patients with a clinical response, ctDNA became undetectable over time. Neuroblastoma is the most common extracranial solid tumour in paediatrics. High-risk disease comprises about half of all diagnoses and long-term survival is poor. Plasma ctDNA has been demonstrated to be present at high levels in neuroblastoma and provides an important tool and surrogate for tumour molecular analyses [1]. The multicentre, open-label, randomised, phase 2 NANT2011-01 trial (NCT02035137) evaluated the diagnostic and therapeutic agent metaiodobenzylguanidine (MIBG) with or without radiation sensitisers for patients with relapsed or refractory neuroblastoma. In a pre-planned exploratory analysis, presented by Dr Kevin Campbell (Dana-Farber Cancer Institute, M...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on